Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FREQ NASDAQ:HOOK NASDAQ:ORPH NASDAQ:RDHL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFREQFrequency Therapeutics$0.30$0.58$0.18▼$16.00$10.94M0.84822,537 shs309,164 shsHOOKHOOKIPA Pharma$1.21-2.0%$1.41$0.72▼$6.77$14.69M0.8981,780 shs30,525 shsORPHOrphazyme A/S$1.43$0.51▼$77.77$30.72M1.681.37 million shs941,400 shsRDHLRedhill Biopharma$2.13$1.92$1.71▼$20.28$4.89M4.22163,546 shs6,953 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFREQFrequency Therapeutics0.00%0.00%0.00%0.00%0.00%HOOKHOOKIPA Pharma+1.65%-2.77%-20.65%+61.84%-77.64%ORPHOrphazyme A/S0.00%0.00%0.00%0.00%0.00%RDHLRedhill Biopharma+2.11%+5.71%+4.93%-11.62%-99.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFREQFrequency TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHOOKHOOKIPA Pharma2.4372 of 5 stars3.25.00.00.00.01.70.6ORPHOrphazyme A/SN/AN/AN/AN/AN/AN/AN/AN/ARDHLRedhill BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFREQFrequency Therapeutics 0.00N/AN/AN/AHOOKHOOKIPA Pharma 2.33Hold$4.50273.44% UpsideORPHOrphazyme A/S 0.00N/AN/AN/ARDHLRedhill Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFREQFrequency Therapeutics$14.07M0.78N/AN/A$1.96 per share0.15HOOKHOOKIPA Pharma$43.95M0.33N/AN/A$4.25 per share0.28ORPHOrphazyme A/SN/AN/AN/AN/A$2.74 per shareN/ARDHLRedhill Biopharma$8.04M0.61N/AN/A($3.66) per share-0.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFREQFrequency Therapeutics-$81.58M-$1.89N/AN/AN/AN/A-107.67%-61.40%N/AHOOKHOOKIPA Pharma-$43.50M-$5.85N/AN/AN/A-785.66%-120.09%-77.14%8/6/2025 (Estimated)ORPHOrphazyme A/S-$97.01MN/A0.00N/AN/AN/AN/AN/AN/ARDHLRedhill Biopharma-$8.27MN/A0.00∞N/AN/AN/AN/AN/ALatest FREQ, RDHL, HOOK, and ORPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025HOOKHOOKIPA Pharma-$0.61-$1.23-$0.62-$1.23$3.38 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFREQFrequency TherapeuticsN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/AORPHOrphazyme A/SN/AN/AN/AN/AN/ARDHLRedhill BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFREQFrequency TherapeuticsN/A5.815.81HOOKHOOKIPA PharmaN/A3.613.61ORPHOrphazyme A/S0.141.80N/ARDHLRedhill BiopharmaN/A0.540.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFREQFrequency Therapeutics13.18%HOOKHOOKIPA Pharma63.88%ORPHOrphazyme A/S10.74%RDHLRedhill Biopharma7.20%Insider OwnershipCompanyInsider OwnershipFREQFrequency Therapeutics16.80%HOOKHOOKIPA Pharma3.30%ORPHOrphazyme A/SN/ARDHLRedhill Biopharma6.81%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFREQFrequency Therapeutics4636.52 million30.39 millionNot OptionableHOOKHOOKIPA Pharma16012.19 million11.79 millionOptionableORPHOrphazyme A/S14135.31 millionN/ANot OptionableRDHLRedhill Biopharma2102.30 million2.14 millionNo DataFREQ, RDHL, HOOK, and ORPH HeadlinesRecent News About These CompaniesRedHill initiates recruitment for expanded Phase 2 opaganib/darolutamide studyJuly 2, 2025 | msn.comRedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate CancerJuly 1, 2025 | prnewswire.comRedHill Biopharma Ltd. (RDHL) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRedHill Biopharma Ltd. (RDHL) Income Statement - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment WinMay 13, 2025 | prnewswire.comRedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology CongressMay 2, 2025 | prnewswire.comRedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107April 28, 2025 | prnewswire.comRedHill Biopharma receives non-compliance letter from NasdaqApril 18, 2025 | markets.businessinsider.comRedHill Biopharma Ltd.: RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity DeficiencyApril 18, 2025 | finanznachrichten.deRedHill Biopharma announces publication in journal on OpaganibApril 17, 2025 | markets.businessinsider.comRedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity DeficiencyApril 17, 2025 | prnewswire.comRedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market DisruptionApril 16, 2025 | prnewswire.comRedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational HighlightsApril 10, 2025 | finanznachrichten.deRedHill Biopharma Announces Full-Year 2024 Financial Results and Operational HighlightsApril 10, 2025 | prnewswire.comRedHill Biopharma to submit UK MAA for TaliciaMarch 18, 2025 | markets.businessinsider.comRedHill to file FDA-approved Talicia for UK marketingMarch 18, 2025 | thepharmaletter.comTRedHill Biopharma Ltd.: RedHill Biopharma to Submit FDA-Approved Talicia for UK Marketing AuthorisationMarch 18, 2025 | finanznachrichten.deRedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing AuthorisationMarch 18, 2025 | prnewswire.comRedHill Biopharma announces plans to advance program for Crohn’s diseaseMarch 13, 2025 | markets.businessinsider.comRedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 ResultsMarch 12, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFREQ, RDHL, HOOK, and ORPH Company DescriptionsFrequency Therapeutics NASDAQ:FREQFrequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.HOOKIPA Pharma NASDAQ:HOOK$1.20 -0.03 (-2.03%) As of 02:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Orphazyme A/S NASDAQ:ORPHOrphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.Redhill Biopharma NASDAQ:RDHL$2.13 0.00 (0.00%) As of 02:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
